Ana Mingorance Email & Phone Number

• Web http://www.draccon.comIndependent consultant providing orphan product strategy, development and operation services with a focus on epilepsy and neurodevelopmental syndromes. Experience with programs that have.
• Pipeline development / Disease strategy: support company strategy in rare epilepsies; identification of potential indications for client programs; competitive intelligence
• Pipeline development: identification and evaluation of assets to in license; evaluation of academic programs for NewCo creation
• Preclinical programs: set up preclinical model and characterization; in vitro and in vivo model design and interpretation; internal communication about best disease fit and program value
• Clinical programs: advice on trial design, clinical outcome measures, clinical operations; source KOL feedback, identify SoC limitations, source patient data
• Regulatory strategy: support with EMA orphan drug development

Chief Development Officer Feb 2018 - October 2021Scientific Advisor October 2021 - August 2023Chief Development Officer September 2023-presentIdentified and managed regulatory and clinical efforts to de-risk the field and accelerate the development of treatments for CDKL5 Deficiency Disorder. Secured disease registration in medical classifications (MedDra.

Accelerating the development of treatments for Phelan-McDermid syndrome (SHANK3).https://www.cureshank.org/

Helping develop treatments for an ultra-rare neurodevelopmental disorder (less than 10 patients described) caused by recessive mutations in the DHPS gene. Supporting therapeutic program development by the DHPS Foundation: https://www.dhpsfoundation.org/

Leiden, South Holland, Netherlands

Rethinking medicine at a cellular level. Drugging cell behavior to make common diseases treatable.

Oslo, Norway

Development of drugs for drug-refractory epilepsy.

Brussels, Brussels Region, Belgium

Expert evaluator for European Commission-funded programs:IMI, Horizon 2020, Horizon Europe, IHI, Eurostars

Madrid Area, Spain

Head of Technology and Innovation 2012-2013 as part-time volunteer while employed by UCB Pharma* Long-term research strategy and R&D project management around Dravet syndrome. * Hosted three international conferences on orphan epilepsies and Dravet syndrome (2014, 2015, 2019)* Published two of the largest epidemiological studies in Dravet syndrome.

Brussels Area, Belgium

* Head of the cellular neurobiology lab. * Project Leader for three first-in-class discovery programs targeting epilepsy and neuropathic pain. * Managed internal multi-disciplinary project teams, including leading a cross-functional project team based in three countries under the UCB-Evotec drug discovery collaboration.

Brussels Area, Belgium

Vancouver, Canada Area

* Dept of Cellular & Physiological Sciences: molecular and cellular basis of brain plasticity.* Recipient of two postdoctoral fellowships from Europe (EMBO) and Canada (MSFHR) to investigate new therapies for the treatment of neurological diseases. * Received four national and international research awards including the prestigious Canadian CIHR Brain Star.

Barcelona Area, Spain

* Faculty of Biology / Parc Cientific de Barcelona. Advisor: Prof. Jose Antonio (Toni) del Rio* Researched the contribution of myelin-associated proteins to preventing neuronal regeneration and their role in brain development. * 8 peer-reviewed publications (4 as first author).* Extraordinary Award to the best PhD thesis defended at the Faculty of Biology.

Ph.D., Neuroscience

PhD Thesis in brain development and regeneration. Extraordinary Award to the best PhD thesis defended at the Faculty of Biology during the.

Cap, Secondary School Teaching Certificate

B.Sc., Cell Biology